A prospective, multicenter, randomised, open-label, active controlled, 2 parallel groups, phase 3 study to compare the efficay and safety of masitinib to sunitinib in patients with gastrointestinal stromal tumor after progression with imitinib

1. patient with histological proven metastatic GIST (gastro-intestinal stromal cancer) or non-operable locally advanced GIST;
2. patient with measurable tumor lesions with longest diameter >=20 mm using conventional techniques or >= 10 mm with spiral CT scan according to Recist 1.1;
3. patient with C-kit (CD117) positive tuimour detected immunohistochemically;
4. patient after progression with imatinib up to 800mg;
5. patient with ECOG <=2;
6.Patient with adequate organ functions;
7. patient with life expectancy >3 months;
8. male or female >18 years;
9. patient with a BMI > 18 kg/m2 and weightening at least 40 kg;

1. patient treated for a cancer other vthan GIST within 5 years before enrolmentwith the exception of basal cell carcinoma or cervical cancer in situ;
2. patient with active CNS metastasis or with history of CNS mtastasis;
3. patient with certain cardiac disorder;
4.patient with history of poor compliance or history of drug/alcohol abuse or excessive alcohol beverage consumption;
5. pregnant or nursing female